Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Direct
Mintz Viewpoints
Showing 2697 - 2704 of 12085 results
Two-Sided Platforms
January 7, 2022| News
As the Clean Water Act Turns 50, Debate Continues Over Its Scope
January 7, 2022| News
(Updated) Shorter COVID-19 Isolation and Quarantine Periods Will Impact Workplaces
January 6, 2022| Blog| Viewpoint
An Overview of Pharmaceutical Sales Representative Licensure and Registration Laws in the United States
January 6, 2022| Blog| Viewpoint
Department of Labor Issues Advice on Broker and Consultant Compensation Disclosures Under the Consolidated Appropriations Act, 2021
January 5, 2022| Blog| Viewpoint
Biden’s Infrastructure Law: Energy & Sustainability Implications
January 5, 2022| Article| Viewpoint
Year in Review: The Most Popular IP Posts of 2021
January 5, 2022| Blog| Viewpoint
Snapshot of Another Much-Too-Busy Year for FDA Before 2022 Really Gets Started
January 5, 2022| Blog| Viewpoint
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts
Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|
Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|